Juno Therapeutics Shareholders Reminded of September 12, 2016 Deadline in Pending Securities Fraud Class Action

BOSTON, MA / ACCESSWIRE / September 6, 2016 / Investors in Juno Therapeutics, Inc. ("Juno" or the "Company") (NASDAQ:JUNO - News) are reminded that the deadline for seeking lead plaintiff status in the pending securities class action against the Company and certain of its officers and directors is September 12, 2016.

The lawsuit alleges that Juno made misleading statements and material omissions regarding a patient death in the Phase 2 "ROCKET" trial of its lead product candidate, JCAR015. In May 2016, a patient in that trial died of a cerebral edema. Juno knew the patient death was important and consulted with the FDA about an appropriate response, yet failed to tell investors.

Instead, in early June, Juno issued a glowing press release that boasted of "[l]ower side effects" and made partial, misleading disclosures - revealing that "Grade 3 or higher neurotoxicity was observed in 15/51 (29%) patients" in a Phase 1 trial but failing to disclose the patient death in May. After two other patients died in late June/early July, the FDA issued a clinical hold and Juno was forced to reveal the truth, in an announcement made after the close of trading on July 7, 2016. The next day, Juno's stock dropped by more than 30%. The clinical hold was lifted shortly after the lawsuit was filed, but the stock still opened today down more than $6/share from its closing price on July 7 - a 15% decline. Juno insiders sold heavily in the weeks prior to these revelations.

Investors who purchased or otherwise acquired Juno securities between June 4, 2016 and July 7, 2016, inclusive are eligible for the class action and consideration as lead plaintiffs and are encouraged to contact Block & Leviton LLP for more information about the lawsuit and how they can participate in it.

If you are interested in becoming a lead plaintiff, have questions about your legal rights, or have information relevant to this investigation, please contact attorney Steven Harte at steven@blockesq.com, by phone at 617-398-5600, or visit http://www.blockesq.com/juno.

Block & Leviton LLP (www.blockesq.com) is a securities litigation firm representing investors nationwide. The firm's lawyers have collectively been prosecuting securities cases on behalf of individual and institutional investors for over 50 years, and have recovered more than a billion dollars on their behalf. Block & Leviton's investigations into corporate wrongdoing were recently covered by the New York Times.

This notice may constitute attorney advertising.

Contact:

BLOCK & LEVITON LLP
Steven Harte
155 Federal St
Boston MA 02110
(617) 398-5600
steven@blockesq.com

SOURCE: Block & Leviton LLP